R
Richard M. Siegel
Researcher at National Institutes of Health
Publications - 249
Citations - 23557
Richard M. Siegel is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Apoptosis & T cell. The author has an hindex of 68, co-authored 243 publications receiving 21301 citations. Previous affiliations of Richard M. Siegel include Rutgers University & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Encoding of spatial location by posterior parietal neurons.
TL;DR: The cortex of the inferior parietal lobule in primates is important for spatial perception and spatially oriented behavior and recordings of single neurons in this area in behaving monkeys showed that the visual sensitivity of the retinotopic receptive fields changes systematically with the angle of gaze.
Journal ArticleDOI
Interleukin-2 Signaling via STAT5 Constrains T Helper 17 Cell Generation
Arian Laurence,Cristina M. Tato,Todd S. Davidson,Yuka Kanno,Zhi Chen,Zhengju Yao,Rebecca Blank,Françoise Meylan,Richard M. Siegel,Lothar Hennighausen,Ethan M. Shevach,John J. O'Shea +11 more
TL;DR: It is demonstrated that in addition to the promotion of activation-induced cell death of lymphocytes and the generation of Treg cells, inhibition of Th17 polarization appears to be an important function of IL-2.
Journal ArticleDOI
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.
Michael J. Lenardo,K M Chan,Felicita Hornung,Hugh I. McFarland,Richard M. Siegel,Jin Wang,Lixin Zheng +6 more
TL;DR: Immunological, cellular, and molecular evidence indicates that throughout the life of a T cell, apoptosis may be evoked in excessive, harmful, or useless clonotypes to preserve a healthy and balanced immune system.
Journal ArticleDOI
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.
Francis Ka-Ming Chan,Hyung J. Chun,Lixin Zheng,Richard M. Siegel,Kimmie L. Bui,Michael J. Lenardo +5 more
TL;DR: A conserved domain in the extracellular region of the 60- and 80-kilodalton tumor necrosis factor receptors was identified that mediates specific ligand-independent assembly of receptor trimers.
Journal ArticleDOI
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara,Mustafa Ozguroglu,Yung-Jue Bang,Maria Di Bartolomeo,Mario Mandalà,Min-Hee Ryu,Lorenzo Fornaro,Tomasz Olesinski,Christian Caglevic,Hyun Cheol Chung,Kei Muro,Eray Goekkurt,Wasat Mansoor,Raymond S. McDermott,Einat Shacham-Shmueli,X. Chen,Carlos Alberto Mayo,S. Peter Kang,Atsushi Ohtsu,Charles S. Fuchs,Guillermo Lerzo,Juan Manuel O'Connor,Guillermo Mendez,James Lynam,Niall C. Tebbutt,Mark Wong,Andrew Strickland,Chris Karapetis,David Goldstein,Paul Vasey,Jean-Luc Van Laethem,Eric Van Cutsem,Scott R. Berry,Mark Vincent,Bettina Muller,Felipe Rey,Angela Zambrano,Joaquin Guerra,Merete Krogh,Lene Baeksgaard,Mette Karen Yilmaz,Anneli Elme,Andrus Magi,Paivi Auvinen,Tuomo Alanko,Markus Moehler,Volker Kunzmann,Thomas Seufferlein,Peter C. Thuss-Patience,Thomas Hoehler,Georg Martin Haag,Salah-Eddin Al-Batran,Hugo Castro,Karla Lopez,Mynor Aguilar Vasquez,Mario Sandoval,Ka On Lam,Sinead Cuffe,Cathy Kelly,Ravit Geva,Ayala Hubert,Alex Beny,Baruch Brenner,Aprile Giuseppe,Alfredo Falcone,Evaristo Maiello,Rodolfo Passalacqua,Vincenzo Montesarchio,Hiroki Hara,Keisho Chin,Tomohiro Nishina,Yoshito Komatsu,Nozumo Machida,Shuichi Hironaka,Taroh Satoh,Takao Tamura,Naotaoshi Sugimoto,Haruhiko Cho,Yashushi Omuro,Ken Kato,Masahiro Goto,Ichinosuke Hyodo,Kazuhiro Yoshida,Hideo Baba,Taito Esaki,Junji Furuse,Wan Zamaniah Wan Mohammed,Carlos Hernandez Hernandez,Juan Casas Garcia,Adriana Dominguez Andrade,Katriona Clarke,Geir Hjortland,Nils Glenjen,Tomasz Kubiatowski,Jassem Jacek,Marek Z. Wojtukiewicz,Sergey Alexandrovich Lazarev,Yuri Lancukhay,Sergey Afanasayev,Vladimir Moiseyenko,Vladimir Kostorov,Svetlana Protsenko,Vadim Shirinkin,Dina Sakaeva,Natalia Fadeeva,Wei Peng Yong,Chau Hsien Matthew Ng,Barbara Robertson,Bernardo Rapaport,Graham Cohen,Lydia Dreosti,Paul Ruff,Conrad Jacobs,Gregory Landers,Waldemar Szpak,Sang-Young Roh,Jeeyun Lee,Yeul Hong Kim,Hyun Cheol Chung,Maria Alsina Maqueda,Federico Longo Munoz,Andres Cervantes Aguilar,Enrique Aranda Aguilar,Pilar Garcia Alfonso,Fernando Rivera,Jaime Feliu Batle,Roberto Pazo Cid,Kun-Huei Yeh,Jen-Shi Chen,Yee Chao,Chia Jui Yen,Oguz Kara,Suayib Yalcin,Daniel Hochhauser,Ian Chau,Al B. Benson,Veena Shankaran,Walid Shaib,Philip A. Philip,Vivek Sharma,Robert J. Siegel,Weijing Sun,Zev A. Wainberg,Ben George,Andrea J. Bullock,Samuel Myrick,Josephine Faruol,Richard M. Siegel,Timothy V. Larson,Carlos Becerra,Suresh Ratnam,Donald A. Richards,Stephen L. Riche +152 more
TL;DR: Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.